Publication: European society of clinical microbiology and infectious diseases guidelines for coronavirus disease 2019: an update on treatment of patients with mild/moderate disease
dc.contributor.coauthor | Bartoletti, M. | |
dc.contributor.coauthor | Azap, O. | |
dc.contributor.coauthor | Barac, A. | |
dc.contributor.coauthor | Bussini, L. | |
dc.contributor.coauthor | Krause, R. | |
dc.contributor.coauthor | Martin Quiros, A. | |
dc.contributor.coauthor | Paño-Pardo, J.R. | |
dc.contributor.coauthor | Power, N. | |
dc.contributor.coauthor | Sibani, M. | |
dc.contributor.coauthor | Szabo, B.G. | |
dc.contributor.coauthor | Tsiodras, S. | |
dc.contributor.coauthor | Zollner-Schwetz, I. | |
dc.contributor.coauthor | Rodríguez-Baño, J. | |
dc.contributor.department | KUH (Koç University Hospital) | |
dc.contributor.department | KUISCID (Koç University İşbank Center for Infectious Diseases) | |
dc.contributor.department | School of Medicine | |
dc.contributor.kuauthor | Ergönül, Önder | |
dc.contributor.schoolcollegeinstitute | KUH (KOÇ UNIVERSITY HOSPITAL) | |
dc.contributor.schoolcollegeinstitute | Research Center | |
dc.contributor.schoolcollegeinstitute | SCHOOL OF MEDICINE | |
dc.date.accessioned | 2024-11-09T11:37:56Z | |
dc.date.issued | 2022 | |
dc.description.abstract | Scope: despite the large availability of vaccines, coronavirus disease 2019 (COVID-19), induced by severe acute respiratory syndrome coronavirus 2, continues to be a major threat for health-care providers and fragile people. A number of options are now available for outpatients with mild-to-moderate COVID-19 at the risk of disease progression for the prevention of deaths or hospitalization. Methods: a European Society of Clinical Microbiology and Infectious Diseases COVID-19 guidelines task force was established by the European Society of Clinical Microbiology and Infectious Diseases Executive Committee. A small group was established, half appointed by the chair and the remaining selected based on an open call. Each panel met virtually once a week. For all decisions, a simple majority vote was used. A long list of clinical questions using the population, intervention, comparison, outcome format was developed at the beginning of the process. For each population, intervention, comparison, outcome, two panel members performed a literature search, with a third panelist involved in case of inconsistent results. Voting was based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Recommendations: in this update, we focus on anti-viral agents, monoclonal antibodies (mAbs) and other treatment options proposed for patients with mild or moderate COVID-19 who are at the risk of hospitalization or death. Although the use of anti-virals is recommended, especially nirmatrelvir/ritonavir and remdesivir or, alternatively, molnupirarvir, the administration of mAbs against the spike protein strictly depends on circulating variants or the ability to test timely for variants and sub-variants. At the time of writing (April–June 2022), the only active mAb was tixagevimab/cilgavimab given the predominance of the Omicron BA.2, BA.3, BA.4 and BA.5 sub-lineages in Europe. However, considering that the epidemiological scenario is extremely dynamic, constant monitoring of variants of concern is mandatory. | |
dc.description.fulltext | YES | |
dc.description.indexedby | WOS | |
dc.description.indexedby | Scopus | |
dc.description.indexedby | PubMed | |
dc.description.issue | 12 | |
dc.description.openaccess | YES | |
dc.description.publisherscope | International | |
dc.description.sponsoredbyTubitakEu | N/A | |
dc.description.sponsorship | N/A | |
dc.description.version | Publisher version | |
dc.description.volume | 28 | |
dc.identifier.doi | 10.1016/j.cmi.2022.08.013 | |
dc.identifier.embargo | NO | |
dc.identifier.filenameinventoryno | IR03819 | |
dc.identifier.issn | 1198-743X | |
dc.identifier.quartile | Q1 | |
dc.identifier.scopus | 2-s2.0-85139318107 | |
dc.identifier.uri | https://doi.org/10.1016/j.cmi.2022.08.013 | |
dc.identifier.wos | 922899400011 | |
dc.keywords | Cilgavimab | |
dc.keywords | COVID-19 | |
dc.keywords | ESCMID | |
dc.keywords | Molnupiravir | |
dc.keywords | Nirmatrelvir/ritonavir | |
dc.keywords | Outpatients | |
dc.keywords | Remdesivir | |
dc.keywords | Sotrovimab | |
dc.keywords | Tixagevimab | |
dc.language.iso | eng | |
dc.publisher | Elsevier | |
dc.relation.grantno | NA | |
dc.relation.ispartof | Clinical Microbiology and Infection | |
dc.relation.uri | http://cdm21054.contentdm.oclc.org/cdm/ref/collection/IR/id/10677 | |
dc.subject | Medicine | |
dc.title | European society of clinical microbiology and infectious diseases guidelines for coronavirus disease 2019: an update on treatment of patients with mild/moderate disease | |
dc.type | Journal Article | |
dspace.entity.type | Publication | |
local.contributor.kuauthor | Ergönül, Mehmet Önder | |
local.publication.orgunit1 | SCHOOL OF MEDICINE | |
local.publication.orgunit1 | KUH (KOÇ UNIVERSITY HOSPITAL) | |
local.publication.orgunit1 | Research Center | |
local.publication.orgunit2 | KUISCID (Koç University İşbank Center for Infectious Diseases) | |
local.publication.orgunit2 | KUH (Koç University Hospital) | |
local.publication.orgunit2 | School of Medicine | |
relation.isOrgUnitOfPublication | f91d21f0-6b13-46ce-939a-db68e4c8d2ab | |
relation.isOrgUnitOfPublication | 09525e58-d4ea-4461-b2ec-f131e54c0771 | |
relation.isOrgUnitOfPublication | d02929e1-2a70-44f0-ae17-7819f587bedd | |
relation.isOrgUnitOfPublication.latestForDiscovery | f91d21f0-6b13-46ce-939a-db68e4c8d2ab | |
relation.isParentOrgUnitOfPublication | 055775c9-9efe-43ec-814f-f6d771fa6dee | |
relation.isParentOrgUnitOfPublication | d437580f-9309-4ecb-864a-4af58309d287 | |
relation.isParentOrgUnitOfPublication | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e | |
relation.isParentOrgUnitOfPublication.latestForDiscovery | 055775c9-9efe-43ec-814f-f6d771fa6dee |
Files
Original bundle
1 - 1 of 1